Best of ASCO - 2014 Annual Meeting

 

Welcome

Local-Regional

Melanoma/Skin Cancers

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A multicenter analysis of melanoma recurrence following adjuvant anti-PD1 therapy.

Carina N. Owen

9502

A phase I study of neoadjuvant combination immunotherapy in locally/regionally advanced melanoma.

Yana Najjar

9586

A population-based model for predicting sentinel lymph node (SLN) status for cutaneous melanoma patients and a clinical decision rule (CDR) for sparing a SLN biopsy (SLNB).

Phyllis A. Gimotty

9589

A sequential dual cohort phase II clinical trial on adjuvant low-dose nivolumab with or without low-dose ipilimumab as adjuvant therapy following the resection of melanoma macrometastases (MM).

Julia Katharina Schwarze

9585

An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238).

Mario Mandalà

9584

Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO).

Dirk Schadendorf

9582

Efficacy of immune checkpoint inhibitors (ICIs) for in-transit melanoma.

Emilia Nan Tie

9583

Ingenol mebutate to treat lentigo maligna of the head (face and scalp): A prospective and multicenter single-arm phase 2 trial.

Henri Montaudié

e21051

Melanoma nodal management in Ontario following ASCO/SSO guidelines.

Steven Latosinsky

e21054

Neoadjuvant cytoreductive treatment with BRAF/MEK inhibition of prior unresectable regionally advanced melanoma to allow complete surgical resection: REDUCTOR trial.

Stephanie A. Blankenstein

9587

Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).

Alexander M. Menzies

9503

Patient-reported outcomes of patients treated with (neo)adjuvant immune checkpoint combination therapy in high-risk stage III macroscopic melanoma: A matched cohort study.

Annelies H. Boekhout

9588

Phase II single-arm multicenter study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma.

Suthee Rapisuwon

TPS9604

Preliminary safety results of a phase II study investigating pembrolizumab in combination with postoperative intensity modulated radiotherapy (IMRT) in resected high risk cutaneous squamous cell cancer of the head and neck.

Shlomo A. Koyfman

e21056

Retrospective analysis of patients with sentinel lymph node (SLN) positive melanoma (MEL) who received adjuvant nivolumab (NIVO) without completion lymph node dissection (CLND).

Zeynep Eroglu

9590

Utility of concurrent immunoradiation for locally advanced and/or medically inoperable melanoma and Merkel cell carcinoma.

Joyson Poulose

e21053